Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
British Columbia and Sacramento, California--(Newsfile Corp. - September 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its
2025-09-19 8:00 AM EDT | Izotropic Corporation
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics" Spotlight Panel at
2025-09-19 7:40 AM EDT | OS Therapies
American Aires Inc. Announces Resignation of Director and Update on Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - September 18, 2025) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the "Company") today announced that Mr. Dimitry Serov ("Mr. Serov") has resigned from the Board of Directors (the "Board") and advised that he will not be standing for re-election at the upcoming annual general meeting of shareholders (the "AGM"), scheduled for Thursday, September 18, 2025. As previously disclosed in the Company's press release dated Augu
2025-09-18 8:00 AM EDT | American Aires Inc.
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced that Phio Pharmaceuticals is a presenting company at the Life Sciences Future Conference to be held September 25 - 26, 2025. Mr. Robert Bitterman, President and CEO of Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-18 7:45 AM EDT | Phio Pharmaceuticals Corp.
Scryb Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 17, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to announce its intention to complete a non-brokered private placement (the "Offering") of up to 6,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit, for gross proceeds of up to $600,000 Each Unit will consist of one common share (a "Common Share") and one half of one common share purchase warrant (each a
Biotechnology, Healthcare and Hospitals, Health
2025-09-17 4:05 PM EDT | Scryb Inc.
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that
Biotechnology, Pharmaceuticals, Health
2025-09-17 7:52 AM EDT | Hemostemix Inc.
Kneat to Present at The Emerging Growth Conference on September 24, 2025
Limerick, Ireland--(Newsfile Corp. - September 16, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that it will be presenting at the Emerging Growth Conference on September 24, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with Kneat's Chief Executive Officer and co-founder, Eddie Ryan, in real time.
2025-09-16 5:12 PM EDT | kneat.com, inc
IR-MED Investor Update Letter - Sept-2025
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today published an investor update. Dear Valued Investors, As we enter September 2025, in addition to Q2 financial reports and to the 8K recently published, I find
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-09-16 4:05 PM EDT | IR-MED, Inc.
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that Croom Lawren
Biotechnology, Pharmaceuticals, Health
2025-09-16 2:52 PM EDT | Hemostemix Inc.
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA to its Board of Directors, effective immediately. Dr. Phinney recently joined Defence as a Strategy and Business Advisor, working closely with leadership to refine the Co
Biotechnology, Pharmaceuticals, Health
2025-09-16 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of $2,000,000 (the "Offering"). Each Unit consisted of (i) on
Biotechnology, Pharmaceuticals, Health
2025-09-15 4:30 PM EDT | Defence Therapeutics Inc.
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
New York, New York--(Newsfile Corp. - September 12, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapi
2025-09-12 7:40 AM EDT | OS Therapies
BYT Announces Corporate Updates
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it has entered into an agreement dated effective September 9, 2025 and sold all of the outstanding shares of its wholly-owned Singapore subsidiary, BYT Engineering PTE Ltd. ("BYT Engineering"), to an arm's length third party for an aggregate purchase price of SGD$10,000. The Company will continue to carry on the business activities of B
Technology, Biotechnology, Construction / Building, Machinery
2025-09-11 5:15 PM EDT | BYT Holdings Ltd.
Nextleaf Provides Strategic Update: Canada's First 200-Pack Cannabis Softgels, and Opening of Distribution Facility
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor announces the launch of Canada's first 200-pack cannabis softgels under its house brand Glacial Gold™, and the opening of a new distribution facility. Together, these developments strengthen Nextleaf's position in existing markets and enh
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-09-11 9:00 AM EDT | Nextleaf Solutions Ltd.
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, a
Biotechnology, Pharmaceuticals, Health
2025-09-10 4:37 PM EDT | Hemostemix Inc.
Izotropic Gains Visibility as AI Market Broadens Beyond Tech
British Columbia and Sacramento, California--(Newsfile Corp. - September 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces its sponsored placement in an editorial published on
2025-09-10 1:24 PM EDT | Izotropic Corporation
Envoy Medical Issues Letter to Shareholders and Provides Update on Recent Accomplishments
White Bear Lake, Minnesota--(Newsfile Corp. - September 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today issued a letter to shareholders commenting on recent accomplishments and other operational updates from Chief Executive Officer, Brent Lucas. Dear Shareholders: The third quarter of 2025 has been one of tremendous progress and momentum for Envoy Medical. As "Amer
Biotechnology, Healthcare and Hospitals
2025-09-10 8:00 AM EDT | Envoy Medical, Inc.
MustGrow Secures $2 Million Line of Credit with CIBC; Guaranteed by EDC
Saskatoon, Saskatchewan--(Newsfile Corp. - September 10, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce it has secured a $2.0 million line of credit with Canadian Imperial Bank of Commerce, guaranteed by Canada's Export Development Canada ("EDC") (the "LOC"). Access to funds will allow MustGrow to produce its organic mustard-derived biofertility product TerraSanteTM
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-09-10 7:00 AM EDT | MustGrow Biologics Corp.
BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
Rehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability
Biotechnology, Pharmaceuticals, Health
2025-09-10 7:00 AM EDT | BioHarvest Sciences Inc.
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces a non broke
Biotechnology, Pharmaceuticals, Health
2025-09-09 8:47 AM EDT | Hemostemix Inc.